Stereotactic body radiotherapy in lung cancer: a contemporary review
Pathol Oncol Res. 2024 Feb 27;30:1611709. doi: 10.3389/pore.2024.1611709. eCollection 2024.ABSTRACTThe treatment of early stage non-small cell lung cancer (NSCLC) has improved enormously in the last two decades. Although surgery is not the only choice, lobectomy is still the gold standard treatment type for operable patients. For inoperable patients stereotactic body radiotherapy (SBRT) should be offered, reaching very high local control and overall survival rates. With SBRT we can precisely irradiate small, well-defined lesions with high doses. To select the appropriate fractionation schedule it is important to determine ...
Source: Pathology Oncology Research - March 13, 2024 Category: Pathology Authors: Emese Csiki Mih ály Simon Judit Papp M árton Barabás Johanna Mik áczó Krist óf Gál David Sipos Árpád Kovács Source Type: research
Stereotactic body radiotherapy in lung cancer: a contemporary review
Pathol Oncol Res. 2024 Feb 27;30:1611709. doi: 10.3389/pore.2024.1611709. eCollection 2024.ABSTRACTThe treatment of early stage non-small cell lung cancer (NSCLC) has improved enormously in the last two decades. Although surgery is not the only choice, lobectomy is still the gold standard treatment type for operable patients. For inoperable patients stereotactic body radiotherapy (SBRT) should be offered, reaching very high local control and overall survival rates. With SBRT we can precisely irradiate small, well-defined lesions with high doses. To select the appropriate fractionation schedule it is important to determine ...
Source: Pathology Oncology Research - March 13, 2024 Category: Pathology Authors: Emese Csiki Mih ály Simon Judit Papp M árton Barabás Johanna Mik áczó Krist óf Gál David Sipos Árpád Kovács Source Type: research
Stereotactic body radiotherapy in lung cancer: a contemporary review
Pathol Oncol Res. 2024 Feb 27;30:1611709. doi: 10.3389/pore.2024.1611709. eCollection 2024.ABSTRACTThe treatment of early stage non-small cell lung cancer (NSCLC) has improved enormously in the last two decades. Although surgery is not the only choice, lobectomy is still the gold standard treatment type for operable patients. For inoperable patients stereotactic body radiotherapy (SBRT) should be offered, reaching very high local control and overall survival rates. With SBRT we can precisely irradiate small, well-defined lesions with high doses. To select the appropriate fractionation schedule it is important to determine ...
Source: Pathology Oncology Research - March 13, 2024 Category: Pathology Authors: Emese Csiki Mih ály Simon Judit Papp M árton Barabás Johanna Mik áczó Krist óf Gál David Sipos Árpád Kovács Source Type: research
Stereotactic body radiotherapy in lung cancer: a contemporary review
Pathol Oncol Res. 2024 Feb 27;30:1611709. doi: 10.3389/pore.2024.1611709. eCollection 2024.ABSTRACTThe treatment of early stage non-small cell lung cancer (NSCLC) has improved enormously in the last two decades. Although surgery is not the only choice, lobectomy is still the gold standard treatment type for operable patients. For inoperable patients stereotactic body radiotherapy (SBRT) should be offered, reaching very high local control and overall survival rates. With SBRT we can precisely irradiate small, well-defined lesions with high doses. To select the appropriate fractionation schedule it is important to determine ...
Source: Pathology Oncology Research - March 13, 2024 Category: Pathology Authors: Emese Csiki Mih ály Simon Judit Papp M árton Barabás Johanna Mik áczó Krist óf Gál David Sipos Árpád Kovács Source Type: research
Stereotactic body radiotherapy in lung cancer: a contemporary review
Pathol Oncol Res. 2024 Feb 27;30:1611709. doi: 10.3389/pore.2024.1611709. eCollection 2024.ABSTRACTThe treatment of early stage non-small cell lung cancer (NSCLC) has improved enormously in the last two decades. Although surgery is not the only choice, lobectomy is still the gold standard treatment type for operable patients. For inoperable patients stereotactic body radiotherapy (SBRT) should be offered, reaching very high local control and overall survival rates. With SBRT we can precisely irradiate small, well-defined lesions with high doses. To select the appropriate fractionation schedule it is important to determine ...
Source: Pathology Oncology Research - March 13, 2024 Category: Pathology Authors: Emese Csiki Mih ály Simon Judit Papp M árton Barabás Johanna Mik áczó Krist óf Gál David Sipos Árpád Kovács Source Type: research
Geroscience and pathology: a new frontier in understanding age-related diseases
In conclusion, the integration of geroscience concepts into pathological research heralds a transformative paradigm shift in our understanding of disease pathogenesis and promises breakthroughs in disease prevention and treatment.PMID:38463143 | PMC:PMC10922957 | DOI:10.3389/pore.2024.1611623 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 11, 2024 Category: Pathology Authors: Monika Fekete David Major Agnes Feher Vince Fazekas-Pongor Andrea Lehoczki Source Type: research
Geroscience and pathology: a new frontier in understanding age-related diseases
In conclusion, the integration of geroscience concepts into pathological research heralds a transformative paradigm shift in our understanding of disease pathogenesis and promises breakthroughs in disease prevention and treatment.PMID:38463143 | PMC:PMC10922957 | DOI:10.3389/pore.2024.1611623 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 11, 2024 Category: Pathology Authors: Monika Fekete David Major Agnes Feher Vince Fazekas-Pongor Andrea Lehoczki Source Type: research
Comprehensive landscape and future perspectives of non-coding RNAs in esophageal squamous cell carcinoma, a bibliometric analysis from 2008 to 2023
Conclusion: Overall, research on ncRNAs in ESCC remains strong. Previous research has mainly focused on the basic research, with a focus on the mechanism of ncRNAs in the occurrence, development, diagnosis, treatment, and prognosis of ESCC. Combining current research with emerging disciplines to further explore its mechanisms of action or shifting the focus of research from preclinical research to clinical research based on diagnosis, treatment, and prognosis, will be the main breakthrough in this field in the future.PMID:38450329 | PMC:PMC10915033 | DOI:10.3389/pore.2024.1611595 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 7, 2024 Category: Pathology Authors: Jiaxin Wu Yuanying Wang Yi Cheng Li Cheng Lushun Zhang Source Type: research
Comprehensive landscape and future perspectives of non-coding RNAs in esophageal squamous cell carcinoma, a bibliometric analysis from 2008 to 2023
Conclusion: Overall, research on ncRNAs in ESCC remains strong. Previous research has mainly focused on the basic research, with a focus on the mechanism of ncRNAs in the occurrence, development, diagnosis, treatment, and prognosis of ESCC. Combining current research with emerging disciplines to further explore its mechanisms of action or shifting the focus of research from preclinical research to clinical research based on diagnosis, treatment, and prognosis, will be the main breakthrough in this field in the future.PMID:38450329 | PMC:PMC10915033 | DOI:10.3389/pore.2024.1611595 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 7, 2024 Category: Pathology Authors: Jiaxin Wu Yuanying Wang Yi Cheng Li Cheng Lushun Zhang Source Type: research
Comprehensive landscape and future perspectives of non-coding RNAs in esophageal squamous cell carcinoma, a bibliometric analysis from 2008 to 2023
Conclusion: Overall, research on ncRNAs in ESCC remains strong. Previous research has mainly focused on the basic research, with a focus on the mechanism of ncRNAs in the occurrence, development, diagnosis, treatment, and prognosis of ESCC. Combining current research with emerging disciplines to further explore its mechanisms of action or shifting the focus of research from preclinical research to clinical research based on diagnosis, treatment, and prognosis, will be the main breakthrough in this field in the future.PMID:38450329 | PMC:PMC10915033 | DOI:10.3389/pore.2024.1611595 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 7, 2024 Category: Pathology Authors: Jiaxin Wu Yuanying Wang Yi Cheng Li Cheng Lushun Zhang Source Type: research
Comprehensive landscape and future perspectives of non-coding RNAs in esophageal squamous cell carcinoma, a bibliometric analysis from 2008 to 2023
Conclusion: Overall, research on ncRNAs in ESCC remains strong. Previous research has mainly focused on the basic research, with a focus on the mechanism of ncRNAs in the occurrence, development, diagnosis, treatment, and prognosis of ESCC. Combining current research with emerging disciplines to further explore its mechanisms of action or shifting the focus of research from preclinical research to clinical research based on diagnosis, treatment, and prognosis, will be the main breakthrough in this field in the future.PMID:38450329 | PMC:PMC10915033 | DOI:10.3389/pore.2024.1611595 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 7, 2024 Category: Pathology Authors: Jiaxin Wu Yuanying Wang Yi Cheng Li Cheng Lushun Zhang Source Type: research
Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
Conclusion: This study is the first to provide insights into the characteristics, treatment patterns, and outcomes of CML patients treated with TKIs in Hungarian clinical practice between 2011 and 2019. We found slightly lower OS rates compared to other European countries, however, there was a statistically significant improvement in 4-year OS during the study period. The management of CML was in line with international guidelines and recommendations.PMID:38444749 | PMC:PMC10913892 | DOI:10.3389/pore.2024.1611497 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 6, 2024 Category: Pathology Authors: Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Judit Demeter Source Type: research
Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
Conclusion: This study is the first to provide insights into the characteristics, treatment patterns, and outcomes of CML patients treated with TKIs in Hungarian clinical practice between 2011 and 2019. We found slightly lower OS rates compared to other European countries, however, there was a statistically significant improvement in 4-year OS during the study period. The management of CML was in line with international guidelines and recommendations.PMID:38444749 | PMC:PMC10913892 | DOI:10.3389/pore.2024.1611497 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 6, 2024 Category: Pathology Authors: Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Judit Demeter Source Type: research
Editorial: Pathology and Oncology Research: addressing publication ethics issues
Pathol Oncol Res. 2024 Feb 14;30:1611691. doi: 10.3389/pore.2024.1611691. eCollection 2024.NO ABSTRACTPMID:38420138 | PMC:PMC10900982 | DOI:10.3389/pore.2024.1611691 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - February 29, 2024 Category: Pathology Authors: J ózsef Tímár Andrea Lad ányi Anna Sebesty én L ászló Kopper Source Type: research
Editorial: Pathology and Oncology Research: addressing publication ethics issues
Pathol Oncol Res. 2024 Feb 14;30:1611691. doi: 10.3389/pore.2024.1611691. eCollection 2024.NO ABSTRACTPMID:38420138 | PMC:PMC10900982 | DOI:10.3389/pore.2024.1611691 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - February 29, 2024 Category: Pathology Authors: J ózsef Tímár Andrea Lad ányi Anna Sebesty én L ászló Kopper Source Type: research
